ArticleBMC cancer2015
Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03694756 (TMEM-MRI), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- The invadosome of stem-like cancer cells: metastasis machinery and targetable vulnerability.Cancer metastasis reviews · 2025Review
- Article
- Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies.Acta pharmacologica Sinica · 2023Review
- Matrix stiffness regulates tumor cell intravasation through expression and ESRP1-mediated alternative splicing of MENA.Cell reports · 2023Article
- Intravital imaging to study cancer progression and metastasis.Nature reviews. Cancer · 2023Review
- Combining TMEM Doorway Score and MenaCancers · 2022Article
- Are We Ready for Migrastatics?Cells · 2021Article
- The role of the tumor microenvironment in tumor cell intravasation and dissemination.European journal of cell biology · 2020Article
- Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis.Cancers · 2020Article
- Scaffold stiffness influences breast cancer cell invasion via EGFR-linked Mena upregulation and matrix remodeling.Matrix biology : journal of the International Society for Matrix Biology · 2020Article
- The emerging roles of macrophages in cancer metastasis and response to chemotherapy.Journal of leukocyte biology · 2019Review
- Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers.Applied immunohistochemistry & molecular morphology : AIMM · 2019Article
- Prediction of clusters of miRNA binding sites in mRNA candidate genes of breast cancer subtypes.PeerJ · 2019Article
- Enah overexpression is correlated with poor survival and aggressive phenotype in gastric cancer.Cell death & disease · 2018Article
- Chemotherapy-induced metastasis: mechanisms and translational opportunities.Clinical & experimental metastasis · 2018Review
- Tumor Cell Invadopodia: Invasive Protrusions that Orchestrate Metastasis.Trends in cell biology · 2017Review
- Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.Science translational medicine · 2017Article
- Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway.Oncogene · 2017Article
- A metastasis biomarker (MetaSiteNPJ breast cancer · 2017Article
- MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundMenacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer.
methodsAnalysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features.
resultsHigh Menacalc was associated with increased risk of death from any cause (P=0.0199, HR (CI)=2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n=142) (P=0.0052, HR (CI)=3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes.
conclusionsMenacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.